Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Net debt increased to USD 28.5bn mainly due to dividend and buybacks, partly offset by strong FCF USD bn -24.5 -4.0 -2.6 0.4 -28.5 -7.4 -0.2 5.8 Dec. 31, 2020 Dividends M&A transactions Free Cash Flow Treasury share transactions, net Others June 30, 2021 45 Investor Relations | Q2 2021 Results U NOVARTIS | Reimagining Medicine

View entire presentation